LDLR and atherosclerosis: The first HeFH mouse model created by in vivo somatic gene editing, which does not pass mutations to the next generation, used AAV8‐delivered CRISPR/Cas9 and disrupted the LDLR gene in mice within 6 weeks, resulting in severe hypercholesterolemia and atherosclerosis.109